FSVVPSPK
FSVVPSPK is an orally active peptide. FSVVPSPK exerts significant anti-adipogenic, antioxidant and anti-inflammatory effects in vitro and in vivo, mainly through activating the HO-1/Nrf2 pathway. FSVVPSPK can be used in research related to obesity and metabolic disorders.
For research use only. We do not sell to patients.
- CAS No.: 2016043-82-4
- Formula: C41H65N9O11
- Molecular Weight:860.01
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All AMPK Isoforms
More
Biological Activity
|
IL-6 |
IL-1β |
HO-1 |
PPARγ |
FSVVPSPK (10-100 μM; 48 h) exhibits no significant cytotoxicity against BMMSC cells, but inhibits intracellular reactive oxygen species (ROS) production[1].
FSVVPSPK (10-100 μM; 7 days) inhibits adipogenic differentiation of BMMSCs by downregulating adipogenic transcription factors, suppressing lipogenic enzyme activity and enhancing lipolysis, with a maximum inhibitory rate of 55.72% on lipid accumulation after treatment at 100 μM for 7 days[1].
FSVVPSPK (10-100 μM; 2-3 days) upregulates the expression of HO-1 in the cytoplasm and Nrf2 in the nucleus of BMMSCs[1].
FSVVPSPK (10-100 μM; 7 days) inhibits the production of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in BMMSCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BMMSCs
-
Concentration:10, 50 and 100 μM
-
Incubation Time:7 d
-
Result:Suppressed the expression of adipogenic transcription factors (PPARγ, SREBP-1, C/EBPα) and adipocyte protein 2 (aP2).
Inhibited lipogenic enzymes (FAS, LPL).
Upregulated lipolysis-related p-HSL.
-
Cell Line:BMMSCs
-
Concentration:10, 50 and100 μM
-
Incubation Time:3 d (HO-1); 2 d (Nrf2)
-
Result:Elevated HO-1 expression in the BMMSCs cytoplasm.
Increased Nrf2 expression within the cell nucleus.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6 weeks old, HFD-induced obesity model)[1]
-
Dosage:1, 10 mg/kg body weight
-
Administration:p.o.; daily; 15 weeks
-
Result:Reduced body weight gain, fat percentage and adipose tissue weight.
Decreased subcutaneous adipose tissue adipocyte size to levels.
Suppressed protein expression of adipogenic transcription factors (PPARγ, SREBP-1, C/EBPα) and lipogenic enzymes (LPL, FAS, aP2), and increased expression of p-HSL and p-AMPK in subcutaneous adipose tissue.
Reduced fasting blood glucose, total cholesterol, LDL, and triglycerides, and increased HDL.
Reduced serum proinflammatory cytokines (IL-6, IL-1β, TNFα), and increased serum antioxidant enzyme activities (CAT, SOD, GPx).
Activated Nrf2 and HO-1 in subcutaneous adipose tissue.
Chemical Information
-
CAS No. 2016043-82-4
-
Molecular Weight 860.01
-
Formula C41H65N9O11
-
Sequence
Phe-Ser-Val-Val-Pro-Ser-Pro-Lys
-
Sequence Shortening
FSVVPSPK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz